Drug Profile
Research programme: anti-sense oligonucleotide therapeutics - nLife
Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator nLife Therapeutics
- Class Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action 5-HT1A serotonin receptor modulators; Antisense RNA modulators; Protein tyrosine phosphatase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Neurogenic inflammation; Obesity
- Discontinued Depressive disorders
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Depressive disorders in Spain (Intranasal)
- 24 Jul 2023 Discontinued - Preclinical for Depressive disorders in Spain (Intrathecal)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Depressive disorders in Spain (Intranasal)